骨质疏松症的诊治及应用间充质干细胞的治疗现状

doi:10.3760/cma.j.issn.1007-1245.2022.03.005

摘要/Abstract

摘要： 骨质疏松症是一种系统性的代谢性骨骼疾病，其特征是骨量减少和骨微结构退化，导致骨骼脆性和骨折风险的增加。在成人中，骨髓间充质干细胞在骨骼中主要分化为成骨细胞和脂肪细胞，当其分化失衡，分化的脂肪细胞增多，成骨细胞减少，最终会演变成骨质疏松症。骨质疏松症越来越被认为是一个主要的公共健康问题，对全世界超过2亿人有影响，每年造成超过890万的骨折，其中以髋骨骨折为主。随着人口老龄化的加剧，花费在骨质疏松症的个人和社会成本逐年增加，这对公共卫生保健体系提出了挑战。因此，早期预防和诊断骨质疏松症的重要性不言而喻。此外，由于间充质干细胞有成骨潜能，且被发现可用于骨骼的修复和维护，自体、异体或转基因骨髓间充质干细胞移植可有效增加骨量和骨密度，增加骨机械强度，纠正骨代谢失衡，其有望成为骨质疏松症治疗的新策略和方法。本文将围绕骨质疏松症的诊断、治疗和间充质干细胞的应用现状展开如下综述。

关键词: 骨质疏松症, 诊断, 治疗方式, 间充质干细胞, 成骨细胞

Abstract: Osteoporosis is a systemic metabolic bone disease characterized by bone loss and bone microstructure degradation, leading to bone fragility and increased risk of fracture. In adults, bone marrow mesenchymal stem cells mainly differentiate into osteoblasts and adipocytes in bone. When their differentiation is unbalanced, differentiated adipocytes increase and osteoblasts decrease, which leads to osteoporosis. Osteoporosis is increasingly regarded as a major public health problem. It affects more than 200 million people all over the world and causes more than 8.9 million fractures every year, mainly hip fractures. With the aggravation of population aging, the personal and social cost spent on osteoporosis is increasing year by year, which poses a challenge to the public health care system. Therefore, the importance of early prevention and diagnosis of osteoporosis is self-evident. In addition, because mesenchymal stem cells have osteogenic potential and are found to be used for bone repair and maintenance, autologous, and allogeneic or transgenic bone marrow mesenchymal stem cell transplantation can effectively increase bone mass, mineral density, and mechanical strength and correct bone metabolic imbalance, it is expected to become a new strategy and method in the treatment of osteoporosis. This paper focuses on the diagnosis and treatment of osteoporosis and the application of mesenchymal stem cells.

Key words: Osteoporosis, Diagnosis, Treatment, Mesenchymal stem cells, Osteoblasts

翁一杰, 黎良盛, 钟向新, 邓妃富, 王义昌, 魏劲松. 骨质疏松症的诊治及应用间充质干细胞的治疗现状[J]. 国际医药卫生导报, 2022, 28(3): 315-320.

Weng Yijie, Li Liangsheng, Zhong Xiangxin, Deng Feifu, Wang Yichang, Wei Jinsong. Diagnosis and treatment of osteoporosis and current status of treatment with mesenchymal stem cells[J]. International Medicine and Health Guidance News, 2022, 28(3): 315-320.

参考文献

[1] Conference CD.Diagnosis, prophylaxis, and treatment of osteoporosis[J]. Am J Med, 1993,94(6):646-650. DOI: 10.1016/0002-9343(93)90218-e.

[2] Singh SV, Tripathi A. An overview of osteoporosis for the practising prosthodontist[J]. Gerodontology, 2010,27(4):308-314. DOI: 10.1111/j.1741-2358.2009.00324.x.

[3] Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report[J]. Osteoporos Int, 1994,4(6):368-381. DOI: 10.1007/BF01622200.

[4] Eriksen EF. Treatment of osteopenia[J]. Rev Endocr Metab Disord, 2012,13(3):209-223. DOI: 10.1007/s11154-011-9187-z.

[5] Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis[J]. Osteoporos Int, 2007,18(4):427-444. DOI: 10.1007/s00198-006-0253-4.

[6] Dawson-Hughes B, Tosteson AN, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA[J]. Osteoporos Int, 2008,19(4):449-458. DOI: 10.1007/s00198-008-0559-5.

[7] Martin TJ, Seeman E. Bone remodelling: its local regulation and the emergence of bone fragility[J]. Best Pract Res Clin Endocrinol Metab, 2008,22(5):701-722. DOI: 10.1016/j.beem.2008.07.006.

[8] Hadjidakis DJ, Androulakis II. Bone remodeling[J]. Ann N Y Acad Sci, 2006,1092:385-396. DOI: 10.1196/annals.1365.035..

[9] Kim BJ, Koh JM. Coupling factors involved in preserving bone balance[J]. Cell Mol Life Sci, 2019,76(7):1243-1253. DOI: 10.1007/s00018-018-2981-y.

[10] Zuo C, Huang Y, Bajis R, et al. Osteoblastogenesis regulation signals in bone remodeling[J]. Osteoporos Int, 2012,23(6):1653-1663. DOI: 10.1007/s00198-012- 1909-x.

[11] Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells[J]. Cell Tissue Kinet, 1970,3(4):393-403. DOI: 10.1111/j.1365-2184. 1970.tb00347.x.

[12] Kassem M, Abdallah BM, Saeed H. Osteoblastic cells: differentiation and trans-differentiation[J]. Arch Biochem Biophys, 2008,473(2):183-187. DOI: 10.1016/j.abb. 2008.03.028.

[13] Dezawa M, Ishikawa H, Itokazu Y, et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration[J]. Science, 2005,309(5732):314-317. DOI: 10.1126/science.1110364.

[14] Rodrigo SF, van Ramshorst J, Hoogslag GE, et al. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up[J]. J Cardiovasc Transl Res, 2013,6(5):816-825. DOI: 10.1007/s12265-013- 9507-7.

[15] Ariffin SH, Manogaran T, Abidin IZ, et al. A Perspective on stem cells as biological systems that produce differentiated osteoblasts and odontoblasts[J]. Curr Stem Cell Res Ther, 2017,12(3):247-259. DOI: 10.2174/1574888X11666161026145149.

[16] Wang Q, Zhao B, Li C, et al. Decreased proliferation ability and differentiation potential of mesenchymal stem cells of osteoporosis rat[J]. Asian Pac J Trop Med, 2014,7(5):358-363. DOI: 10.1016/S1995-7645(14)60055-9.

[17] Hu L, Yin C, Zhao F, et al. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment[J]. Int J Mol Sci, 2018,19(2):360. DOI: 10.3390/ijms19020360.

[18] Tokuzawa Y, Yagi K, Yamashita Y, et al. Id4, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiation[J]. PLoS Genet, 2010,6(7):e1001019. DOI: 10.1371/journal.pgen.1001019.

[19] Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older[J]. N Engl J Med, 1997,337(10):670-676. DOI: 10.1056/NEJM199709043371003.

[20] Baccaro LF, Conde DM, Costa-Paiva L, et al. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil[J]. Clin Interv Aging, 2015,10:583-591. DOI: 10.2147/CIA.S54614.

[21] 陈镜,冯正平.骨质疏松症治疗药物研究进展[J].中国骨质疏松杂志,2021,27(5):776-780.DOI:10.3969/j.issn.1006-7108.2021.05.029.

[22] Phetfong J, Sanvoranart T, Nartprayut K, et al. Osteoporosis: the current status of mesenchymal stem cell-based therapy[J]. Cell Mol Biol Lett, 2016,21:12. DOI: 10.1186/s11658-016-0013-1.

[23] Shi Z, Zhou H, Pan B, et al. Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis[J]. PLoS One, 2016,11(12):e0168691. DOI: 10.1371/journal.pone.0168691.

[24] Lombardi G, Di Somma C, Rubino M, et al. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics[J]. J Endocrinol Invest, 2011,34(7 Suppl):18-22.

[25] Corrado A, Sanpaolo ER, Di Bello S, et al. Osteoblast as a target of anti-osteoporotic treatment[J]. Postgrad Med, 2017,129(8):858-865. DOI: 10.1080/00325481.2017. 1362312.

[26] Lindsay R, Krege JH, Marin F, et al. Teriparatide for osteoporosis: importance of the full course[J]. Osteoporos Int, 2016,27(8):2395-2410. DOI: 10.1007/s00198-016- 3534-6.

[27] Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis[J]. N Engl J Med, 2007,357(9):905-916. DOI: 10.1056/NEJMra067395.

[28] Van Beek ER, Löwik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors[J]. Bone, 2002,30(1):64-70. DOI: 10.1016/s8756-3282(01)00655-x.

[29] Rodan GA, Reszka AA. Bisphosphonate mechanism of action[J]. Curr Mol Med, 2002,2(6):571-577. DOI: 10.2174/1566524023362104.

[30] Rogers MJ, Crockett JC, Coxon FP,et al. Biochemical and molecular mechanisms of action of bisphosphonates[J]. Bone, 2011,49(1):34-41. DOI: 10.1016/j.bone.2010. 11.008.

[31] Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome[J]. Osteoporos Int, 2007,18(10):1363-1370. DOI: 10.1007/s00198-007-0384-2.

[32] Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study[J]. J Bone Miner Res, 2009,24(6):1095-1102. DOI: 10.1359/jbmr.081247..

[33] Deal C. Potential new drug targets for osteoporosis[J]. Nat Clin Pract Rheumatol, 2009,5(1):20-27. DOI: 10.1038/ncprheum0977.

[34] Martin A, Xiong J, Koromila T, et al. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association[J]. Bone, 2015,75:96-104. DOI: 10.1016/j.bone.2015.02.007.

[35] Rodríguez JP, Astudillo P, Ríos S, et al. Involvement of adipogenic potential of human bone marrow mesenchymal stem cells (MSCs) in osteoporosis[J]. Curr Stem Cell Res Ther, 2008,3(3):208-218. DOI: 10.2174/157488808785740325.

[36] Kim RY, Yang HJ, Song YM, et al. Estrogen modulates bone morphogenetic protein-induced sclerostin expression through the wnt signaling pathway[J]. Tissue Eng Part A, 2015,21(13-14):2076-2088. DOI: 10.1089/ten.TEA.2014. 0585.

[37] Post S, Abdallah BM, Bentzon JF, et al. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells[J]. Bone, 2008,43(1):32-39. DOI: 10.1016/j.bone.2008.03.011.

[38] Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women[J]. N Engl J Med, 2006,355(2):125-137. DOI: 10.1056/NEJMoa062462.

[39] Paspaliaris V, Kolios G. Stem cells in osteoporosis: from biology to new therapeutic approaches[J]. Stem Cells Int, 2019,2019:1730978. DOI: 10.1155/2019/1730978.

[40] Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis[J]. Osteoporos Int, 2011,22(6):1659-1667. DOI: 10.1007/s00198-010-1369-0.

[41] Reginster JY, Brandi ML, Cannata-Andía J, et al. The position of strontium ranelate in today's management of osteoporosis[J]. Osteoporos Int, 2015,26(6):1667-1671. DOI: 10.1007/s00198-015-3109-y.

[42] 钟旭丽,封宇飞,张君莉.新型骨吸收抑制剂地诺单抗的药理与临床研究[J].中国新药杂志,2011,20(5):389-392.

[43] Chen J, Smerdely P. Hypocalcaemia after denosumab in older people following fracture[J]. Osteoporos Int, 2017,28(2):517-522. DOI: 10.1007/s00198-016-3755-8.

[44] Liu L, Webster TJ. In situ sensor advancements for osteoporosis prevention, diagnosis, and treatment[J]. Curr Osteoporos Rep, 2016,14(6):386-395. DOI: 10.1007/s11914-016-0339-7.

[45] Kolios G. Animal models of inflammatory bowel disease: how useful are they really?[J]. Curr Opin Gastroenterol, 2016,32(4):251-257. DOI: 10.1097/MOG. 0000000000000287.

[46] Ye X, Zhang P, Xue S, et al. Adipose-derived stem cells alleviate osteoporosis by enhancing osteogenesis and inhibiting adipogenesis in a rabbit model[J]. Cytotherapy, 2014,16(12):1643-1655. DOI: 10.1016/j.jcyt.2014. 07. 009.

[47] Lien CY, Chih-Yuan Ho K, Lee OK, et al. Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells[J]. J Bone Miner Res, 2009,24(5):837-848. DOI: 10.1359/jbmr.081257.

[48] Chen HT, Lee MJ, Chen CH, et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures[J]. J Cell Mol Med, 2012,16(3):582-593. DOI: 10.1111/j.1582-4934.2011.01335.x.

[49] Iaquinta MR, Mazzoni E, Bononi I, et al. Adult stem cells for bone regeneration and repair[J]. Front Cell Dev Biol, 2019,7:268. DOI: 10.3389/fcell.2019.00268.

[50] Parikh SN. Gene therapy: principles and clinical applications in orthopedics[J]. Orthopedics, 2004,27(3):294-303; quiz 304-305. DOI: 10.3928/0147-7447- 20040301-14.

[51] Centeno CJ, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells[J]. Pain Physician, 2008,11(3):343-353.

[52] Lee DS, Choung HW, Kim HJ, et al. NFI-C regulates osteoblast differentiation via control of osterix expression[J]. Stem Cells, 2014,32(9):2467-2479. DOI: 10.1002/stem.1733.

[53] James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation[J]. Scientifica (Cairo), 2013,2013:684736. DOI: 10.1155/2013/684736.

[54] Lin GL, Hankenson KD. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation[J]. J Cell Biochem, 2011,112(12):3491-3501. DOI: 10.1002/jcb.23287.

[55] Kim D, Cho SW, Her SJ, et al. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice[J]. Stem Cells, 2006,24(7):1798-1805. DOI: 10.1634/stemcells. 2005-0480.

[56] Sanchez-Fernandez MA, Gallois A, Riedl T, et al. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling[J]. PLoS One, 2008,3(10):e3537. DOI: 10.1371/journal.pone.0003537.

[57] Lim RZL, Li L, Yong EL, et al. STAT-3 regulation of CXCR4 is necessary for the prenylflavonoid Icaritin to enhance mesenchymal stem cell proliferation, migration and osteogenic differentiation[J]. Biochim Biophys Acta Gen Subj, 2018,1862(7):1680-1692. DOI: 10.1016/j.bbagen. 2018.04.016.

[58] Zhao YM, Li JY, Lan JP, et al. Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells[J]. Biochem Biophys Res Commun, 2008,369(4):1114-1119. DOI: 10.1016/j.bbrc. 2008.03.011.